A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy for LHON has been restricted to supportive measures rather than cure.10”
From Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Patients only able to count fingers, detect hand motion or light perception were assigned logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).”
BackgroundInfluentialRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 3×
“Most remain legally blind, are unable to drive a motor vehicle, and are unable to find employment (Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen et al., 1996).”
BackgroundResultInfluentialThe epidemiology of mitochondrial disorders—past, present and future
Schaefer, A. M., Taylor, R. W., Turnbull, D. M., & Chinnery, P. F. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.09.005 · Cited by 396 · cited 1×
“Inherited disorders of mitochondrial energy metabolism are a major cause of metabolic disease affecting more than 1/5000 of the population (Schaefer et al., 2004).”
BackgroundSelf-citationBARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247 · cited 14×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundInfluential
Research works printed but not linked: 1
- Harding AE Sweeney MG Govan GG Riordan-Eva P Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation Am J Hum Genet 1995 57 77 86 7611298 PMC1801226
Cited by
Items 501–574 of 574
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0007
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0013
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0005
Miléa, D. (2019) · Current practices in ophthalmology · doi:10.1007/978-981-13-8522-3_4
Goumalatsou, C. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0002
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0011
Kullmann, D. M. (2016) · Brain · doi:10.1093/brain/aww058
Denniston, A. K., & Mathewson, P. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0004
Hjelde, N. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0011
Graham, B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0009
Irani, N. K., O’Connor, K. D. J., & Lock, J. H. (2022) · Neurology · doi:10.1212/wnl.0000000000201154
Clinical application of multicolor imaging in Leber hereditary optic neuropathy
Cheng, Y., He, L., Miao, Q., Wang, W., Yuan, J., & Chen, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1003514
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0004
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0010
JABC, & JML (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0008
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0007
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0002
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0003
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0011
Reference intervals—biochemistry
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.002.0012
Reference intervals—haematology
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.002.0013
Peragallo, J. H., Biousse, V., & Newman, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6616-0.00054-2
Current and Emerging Therapies for Leber Hereditary Optic Neuropathy
Davila-Siliezar, P. A., Laylani, N. A. R., Douglas, K. A. A., Miléa, D., & Lee, A. G. (2023) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2023.17.1.21
Leber Hereditary Optic Neuropathy: A Teenager with Painless Sequential Vision Loss
Gilbert, A. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-16147-6_19
Silva, V. D. O. E., Mendes, J. K. D. S., de Barros, V. A., Maximino, M. D. S., Medeiros, L., & da Silva, A. H. P. (2023) · Revista Brasileira de Oftalmologia · doi:10.37039/1982.8551.20230041
Hereditäre Optikusneuropathien
Rüther, K. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-65929-8_75-1
Migräne und mitochondriale Erkrankungen
Hämmerl, L., & Kraya, T. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01622-8
Leber hereditary optic neuropathy
(2024) · International Research Journal of Modernization in Engineering Technology and Science · doi:10.56726/irjmets49882
Masuda, Y., Ishikawa, H., Ishikawa, H., Kezuka, T., Miyazaki, A., Matsumoto, K., Gomi, F., Mimura, O., Shikishima, K., Nakano, T., et al. (2024) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-024-01077-z
“Although European and Japanese studies report positive outcomes, the need for sensitive and objective visual function assessments remains given the limitations of subjective measures in LHON's severe central visual field defects [6–8].”
Jørstad, Ø. K., Skaar, S., Strand, H., Røsby, O., Brokstad, R. T., & Rønning, P. A. (2024) · Case Reports in Ophthalmology · doi:10.1159/000539445
“With regard to treatment of LHON, one randomized controlled trial suggests bene fi t of idebenone [2].”
MethodMitochondrial disorders due to mutations in the nuclear genome
Chinnery, P. F., & Horváth, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00055-8
Self-citationKim, S., Shih, G. C., & Brooks, B. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-815234-8.00005-7 · Cited by 1
Trials in Neuro-ophthalmology: An Overview
Sharma, A., & Madan, S. (2023) · Delhi Journal of Ophthalmology · doi:10.4103/dljo.dljo_61_23
Leber Hereditary Optic Neuropathy: Still a Dilemma?
Satish, N. M., Rath, S. S., Chopra, K., Khurana, R., Chawla, N., & Guliani, B. P. (2022) · Delhi Journal of Ophthalmology · doi:10.4103/dljo.dljo_74_23
Horiuchi, K., Nakamura, S. N., & Yamada, K. (2025) · Cureus · doi:10.7759/cureus.80439 · Cited by 1
Hassan, A. K., & Serhan, H. A. A. (2025) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2898_23
“Most of the studies were published in 2021, with five studies being published in 2021, [12–16] followed by 2020 with four studies, [17–20] two studies being published in 2016 [21,22] and 2022 [23,24] each, and one study each in 2011, [5] 2013, [6] 2019, [25] and 2023 [26] [Fig .”
InfluentialAnimal Models in Neuro Ophthalmology
Normando, E. M., Sher, A., Patel, R. P., Arora, N., & Cordeiro, M. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-72156-4_19
Hereditäre Optikusneuropathien
Rüther, K. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65823-9_75
Acute Bilateral Vision Loss in a Young Male: A Case of Leber’s Hereditary Optic Neuropathy
Hilali, Z., Korno, O. E., Laarif, Y., BOUTIMZINE, N., & Cherkaoui, L. O. (2025) · Cureus · doi:10.7759/cureus.86607
“While various nutritional supplements have been tested, none have proven effective in large clinical trials [11].”
InfluentialShah, V. S., Coussa, R. G., & Traboulsi, E. I. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0043
Pacheco, M. C. S. M. A., María Cabarcas, S., & Godin, F. (2022) · Oftalmología clínica y experimental. · doi:10.70313/2718.7446.v15.n1.118
IT TAKES TWO TO TANGO: potential novel therapies for autosomal dominant optic atrophy
Sampige, R. R., Seaborn, L. E. A., Pluenneke, M., Jyothi, A., Saland, S., Chinedu-Obi, C. M., Keehn, C. C., & Lee, A. G. (2025) · Frontiers in Ophthalmology · doi:10.3389/fopht.2025.1688232
Beidseitige Visusverschlechterung bei exzessivem Tabak- und Alkoholkonsum
Cyrus-Hajmassy, M. (2012) · Der Ophthalmologe · doi:10.1007/s00347-012-2604-1
Neurometabolische und neurodegenerative Krankheiten
Gärtner, J., Körner, C., Kohlschütter, A., Muschol, N., Schneider, S. A., Spiekerkoetter, U., Steinfeld, R., Thiel, C., & Wilichowski, E. (2014) · Elsevier eBooks · doi:10.1016/b978-3-437-23076-9.00005-x
Haque, S., Crawley, K., SCHOFIELD, D. J., Shrestha, R. N., & Sue, C. (2024) · Figshare · doi:10.6084/m9.figshare.27019272
Evaluation of a Child With Optic Atrophy
Koester, K. H., & Ditta, L. C. (2026) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000608
Menna, F., Pinelli, C., Luca, L. D., Meduri, A., Baldascino, A., Lupo, S., & Vingolo, E. M. (2026) · Biomedicines · doi:10.3390/biomedicines14040782
“Consequently, even subtle impairments in mitochondrial function can precipitate selective RGC degeneration [11,24,25].”
Ophthalmic manifestations of mitochondrial disorders
Baxter, M. F., Borchert, G. A., Blakely, E. L., Ruan, C. W., MacLaren, R. E., McFarland, R., & Taylor, R. W. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101466 · Cited by 2
Takai, Y., Yamagami, A., Iwasa, M., Inoue, K., Yasumoto, R., Ishikawa, H., & Wakakura, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348093
Ansong‐Ansongton, Y. O. N., Bamac, D. Z., & Rivers, A. E. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.05.003 · Cited by 1
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0005
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0010
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0008
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0015
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0003
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0002
JABC, & JML (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0006
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0011
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0012
Targeting mtDNA to Modulate Mitochondrial Dysfunction in Neurodegenerative Diseases
Pramanik, S., Debnath, B., Chakraborty, A. J., Islam, A., Mullick, S., Chaudhary, P., Nath, R., Chellappan, D. K., Mondal, M., & Ashique, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06008-2 · Cited by 1
“The prevention of additional vision loss and enhancement of vision clarity have been demonstrated in clinical studies [168].”
Coutinho, C. P., Zanchetta, F., Carbonelli, M., Battista, M., Galzignato, A., Morgia, C. L., Amore, G., Romagnoli, M., Brotto, L., Nucci, P., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.8.8
“24,25 The Mann–Whitney U test was performed to statistically compare if an AT loss pattern was more prevalent in one of the two groups.”
A review of the optical coherence tomography angiography in neuro-ophthalmology
Dedina, L., Cugati, S., & Chen, C. S. (2026) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo-d-25-00211 · Cited by 1
Ambika, S., & Sundaramurthy, S. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1696_25
“[90,91] Unlike ubiquinone, idebenone crosses the blood–brain barrier.”
Leber’s hereditary optic nerve atrophy
Orenburkina, O. I., Frolov, M. A., Babushkin, A. E., Vorobyeva, I. V., Фролов, М. А., & Koshelev, D. I. (2026) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2026142041105
Karaa, A., Sanchez, M. I. G. L., Stuart, C., Bolliger, L., Murray, K., O'Hanlon, M. E., Tseng, B., Yeske, P. E., & Murray, S. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261473291
Omics in optic neuropathies: From molecular landscapes to personalized therapeutics
Wu, S., Tan, K., Qiu, M., Chen, Y., Li, J., Hu, Y., & Zhou, H. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101526
Monici, G., Cascio, F. L., Parisi, G., Marolo, P., Reibaldi, M., & Borrelli, E. (2026) · Neuroretina · doi:10.1007/s44448-026-00005-x
Zhang, X., Chang, A., Liu, Y., & Yu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1935135
Hedström, J., Nilsson, M., Fagerström, S., Engvall, M., Williams, P. A., & Venkataraman, A. P. (2026) · Eye · doi:10.1038/s41433-026-04866-7
Mitochondrial Myopathy in the Oculoplastic Practice
Cheong, A. J. Y., Ding, J., Lim, Z. W., Chen, W., Tan, K. B., Romero, M. C., & Lim, B. X. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197646
“Idebenone, a short-chain synthetic CoQ10 analogue, offers improved aqueous solubility and blood–brain barrier penetration, and has demonstrated efficacy in LHON [45].”
Leber Optic Atrophy (Leber Hereditary Optic Neuropathy; LHON)
Mohamadi, M. H. (2025) · Springer eBooks · doi:10.1007/978-3-319-66816-1_599-1
A clinical case of autosomal recessive Leber hereditary optic neuropathy in an adolescent
Катаргина, Л. А., Denisova, E. V., & Khrabrova, M. A. (2026) · Russian Pediatric Ophthalmology · doi:10.17816/rpoj708213
Krawczynski, M. R., Everdingen, J. V., Leroy, B. P., Verny, C., Bauer, N. J. C., Andris, C., Lorenz, B., Votruba, M., Priglinger, C., Jurkutė, N., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14181-6
“However, it must be kept in mind that approaches to measure off-chart VA vary among different studies and can impact the comparability of some results [21, 42].”
Self-citationHorváth, R., & Lombès, A. (2013) · Springer eBooks · doi:10.1007/978-3-642-40337-8_16
Metadata
- Authors
- Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., & Chinnery, P. F.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- 2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospital, NE1 4LP, NHS Trust, UK
- Centre Hospitalier de l’Université de Montréal (CA)
- Royal Victoria Infirmary (GB)
- Santhera Pharmaceuticals (Switzerland) (CH)
- 8 4Pharma, Stockholm, 16440 Kista, Sweden
- Corresponding author
- Chinnery, Patrick F.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-23
- Volume
- 134
- Issue
- 9
- Pages
- 2677-2686
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3170530
- OpenAlex
- W2124154990
- Cited by
- 578
- References
- 32
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 41 · 2023: 36 · 2022: 44 · 2021: 42 · 2020: 69 · 2019: 39 · 2018: 31 · 2017: 28 · 2016: 61 · 2015: 28 · 2014: 28 · 2013: 29 · 2012: 29
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (01GM0862)
- National Institute for Health and Care Research (NF-SI-0509-10011)
- Parkinson's UK
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung (01GM0862)
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- idebenone, Leber's hereditary optic neuropathy, mitochondrial DNA mutations, mitochondrial disease, visual acuity, retinal nerve fiber layer thickness, treatment response heterogeneity, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antioxidants, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Placebos, Prospective Studies, Retina, Ubiquinone, Visual Acuity, Contrast Sensitivity, Optic Atrophy, Hereditary, Leber, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.